EUSA Pharma

EUSA Pharma

Pharmaceutical company developing and licensing late-stage oncology, pain control, and critical care products. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
€33—50m (Dealroom.co estimates Jun 2007.)
Company register number 09329429
Hemel Hempstead England (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022
Revenues21.3m38.0m63.2m81.6m168m135m146m
% growth16 %79 %66 %29 %106 %(20 %)8 %
EBITDA<1m2.0m50.0m(1.0m)30.0m32.8m17.0m
% EBITDA margin-5 %79 %(1 %)18 %24 %12 %
Profit(5.4m)(7.5m)30.1m(26.4m)9.2m6.0m(4.4m)
% profit margin(26 %)(20 %)48 %(32 %)5 %4 %(3 %)

Source: Dealroom estimates

  • Edit

Recent News about EUSA Pharma

Edit
More about EUSA Pharmainfo icon
Edit

EUSA Pharma is a dynamic, global specialty pharmaceutical company focused on developing and commercializing innovative medicines for oncology and rare diseases. The company serves patients worldwide, aiming to make a meaningful difference in their lives by providing access to life-changing treatments. EUSA Pharma operates in the pharmaceutical market, targeting both healthcare professionals and patients who require specialized therapies. The business model revolves around research and development, clinical trials, regulatory approvals, and the commercialization of its products. Revenue is generated through the sale of its pharmaceutical products, which are distributed globally. The company is committed to expanding its product portfolio and reaching more patients in need.

Keywords: oncology, rare diseases, innovative medicines, global distribution, clinical trials, regulatory approvals, patient-focused, specialty pharmaceuticals, healthcare professionals, life-changing treatments.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by EUSA Pharma

Edit
Cytogen Corporation
ACQUISITION by EUSA Pharma May 2008